Tafasitamab - Incyte Corporation
Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; ICP-B04; INCMOR0208; Minjuvi; Monjuvi; MOR 208; MOR-00208; Tafasitamab-cxix; XENP-5574; XmAb-5574Latest Information Update: 25 Jul 2024
At a glance
- Originator Xencor
- Developer Incyte Corporation; InnoCare Pharma; Knight Therapeutics; MorphoSys; Pfizer; University Medical Center of the Johannes Gutenberg University Mainz; Xencor
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diffuse large B cell lymphoma
- Phase III Follicular lymphoma; Marginal zone B-cell lymphoma
- Phase II B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 20 Jun 2024 Preregistration for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater, In adults) in China (IV)
- 18 Jun 2024 Incyte Corporation plans a phase II Extension trial for Haematological malignancies (IV) in June 2024 (NCT06465433)
- 14 Jun 2024 Efficacy and adverse events data from the phase II trial in Diffuse large B cell lymphoma released by InnoCare Pharma